Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Altimmune
Biotech
Altimmune touts 'best-in-class' lean mass data in weight loss
After a full data analysis, Altimmune is heralding ph. 2 pemvidutide data as “best-in-class” for spurring weight loss while preserving lean mass.
Annalee Armstrong
Jun 23, 2024 1:45pm
Altimmune bails on hepatitis B after phase 2 data disappoint
Mar 27, 2024 7:57am
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Mar 15, 2024 10:55am
Altimmune puts heart health at center of phase 2 obesity data
Dec 1, 2023 8:18am
Analyst sees path for Altimmune obesity drug despite stock drop
Mar 22, 2023 10:27am
Altimmune hits NASH target in phase 1 trial
Sep 14, 2022 11:45am
